Literature DB >> 6814633

Bromocriptine-associated hyponatraemia in cirrhosis.

A W Marshall, A W Jakobovits, M Y Morgan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814633      PMCID: PMC1500543          DOI: 10.1136/bmj.285.6354.1534

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  4 in total

1.  Aldosterone and dopamine receptors in the kidney: sites for pharmacologic manipulation of renal function.

Authors:  W R Adam
Journal:  Kidney Int       Date:  1980-11       Impact factor: 10.612

Review 2.  Prolactin as a regulator of fluid and electrolyte metabolism in mammals.

Authors:  D F Horrobin
Journal:  Fed Proc       Date:  1980-06

3.  Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy.

Authors:  M Y Morgan; A W Jakobovits; I M James; S Sherlock
Journal:  Gastroenterology       Date:  1980-04       Impact factor: 22.682

4.  The effect of bromocriptine on circulating vasopressin.

Authors:  B G Robinson; P Clifton-Bligh; S Posen; B J Morris
Journal:  Clin Sci (Lond)       Date:  1982-10       Impact factor: 6.124

  4 in total
  5 in total

Review 1.  The treatment of hepatic encephalopathy.

Authors:  Marsha Y Morgan; A Blei; K Grüngreiff; R Jalan; G Kircheis; G Marchesini; O Riggio; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 2.  Pathogenesis, diagnosis, and treatment of hepatic encephalopathy.

Authors:  Dileep K Atluri; Ravi Prakash; Kevin D Mullen
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

3.  Hyponatraemia and dopaminergic agents.

Authors:  A J Larner
Journal:  Postgrad Med J       Date:  1994-04       Impact factor: 2.401

Review 4.  Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management.

Authors:  T Y Chan
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 5.  A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors:  J Webster
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.